Calcium, vitamin D in older women
This article was originally published in The Tan Sheet
Executive Summary
Postmenopausal women did not experience a drop in blood pressure or hypertension risk after seven years of calcium plus vitamin D3 supplementation, says a study published in the November issue of the American Heart Association's Hypertension journal. In the randomized, placebo-controlled trial, researchers led by Karen L. Margolis of Minneapolis-based HealthPartners Research Foundation assigned 36,282 subjects to take 1,000 mg of elemental calcium plus 400 IU of vitamin D3 daily or a placebo. The report says the trial was longer than other studies and lost few subjects during follow-up. The large subject pool allowed researchers to study subgroups hypothesized to benefit more from calcium and vitamin D, including blacks, Asians and hypertensive women. No subgroup displayed signs of benefiting from the supplement, the study says. A study of U.S. men and women published July 2007 found an inverse link between vitamin D levels and blood pressure (1"The Tan Sheet" Aug. 13, 2007, p. 10)
You may also be interested in...
Vitamin D Levels Inversely Associated With Hypertension – Study
Low levels of vitamin D were associated with high blood pressure among a large sample of the U.S. population, according to the results of a study in the July issue of the American Journal of Hypertension
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.